The future of endocrine treatment in early prostate cancer : Concluding remarksSCHRÖDER, F. H.European urology. 1999, Vol 36, pp 27-30, issn 0302-2838, SUP2Conference Paper

5α-reductase inhibitors and prostatic diseaseSCHRÖDER, F. H.Clinical endocrinology (Oxford. Print). 1994, Vol 41, Num 2, pp 139-147, issn 0300-0664Article

Radikale Prostatektomie und adjuvante endokrine Behandlung beim lymphogen metastasierten Prostatakarzinom?SCHRÖDER, F. H.Der Urologe. Ausgabe A. 1991, Vol 30, Num 6, pp 417-422, issn 0340-2592Article

Adjuvant endocrine treatment in early prostatic cancerSCHRODER, F. H.Acta oncologica (Stockholm). 1991, Vol 30, Num 2, pp 255-258, issn 0284-186X, 4 p.Conference Paper

What is the optimal treatment for early prostatic cancer ? Summary of the discussionSCHRODER, F. H.Acta oncologica (Stockholm). 1991, Vol 30, Num 2, pp 247-249, issn 0284-186X, 3 p.Conference Paper

Hormonal therapy - A growing role in early prostate cancer, EAU satellite symposium proceedings, Stockholm, April 7, 1999SCHRÖDER, F. H.European urology. 1999, Vol 36, issn 0302-2838, 32 p., SUP2Conference Proceedings

European randomized study of screening for prostate cancer: achievements and presentationROOBOL, M. J; SCHRÖDER, F. H.BJU international. Supplement (Print). 2003, Vol 92, Num 2, pp 117-122, issn 1465-5101, 6 p.Article

Early versus deferred hormone therapy early versus deferred hormone therapyANDERSON, J. B.European urology. 1999, Vol 36, pp 9-13, issn 0302-2838, SUP2Conference Paper

PSA screening for prostate cancer : The current controversy : Prostate specific antigen testing as screening for prostate cancer: The current controversyDE KONING, H. J; SCHRÖDER, F. H.Annals of oncology. 1998, Vol 9, Num 12, pp 1293-1296, issn 0923-7534Article

Epidemiologie und natürlicher Verlauf der benignen Prostatahyperplasie (BPH) = Epidemiology and natural history of BPHBLOM, J. H. M; SCHRÖDER, F. H.Der Urologe. Ausgabe A. 1992, Vol 31, Num 3, pp 129-134, issn 0340-2592Article

Analysis of sonographic pattern in prostatic cancer : comparison of longitudinal and transversal transrectal ultrasound with subsequent radical prostatectomy specimensJANSEN, H; GALLEE, M. P; SCHRÖDER, F. H et al.European urology. 1990, Vol 18, Num 3, pp 174-178, issn 0302-2838, 5 p.Article

Antiandrogens as monotherapy for prostate cancerSCHRÖDER, F. H.European urology. 1998, Vol 34, pp 12-17, issn 0302-2838, SUP3Conference Paper

The European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results, 1994-2003ROOBOL, M. J; SCHRÖDER, F. H.BJU international. Supplement (Print). 2003, Vol 92, Num 2, issn 1465-5101, 127 p.Serial Issue

The natural history of early prostate cancer and the impact of endocrine treatmentADOLFSSON, J.European urology. 1999, Vol 36, pp 3-8, issn 0302-2838, SUP2Conference Paper

Evaluation of prostate-specific antigen in untreated prostatic carcinomaOOSTEROM, R; BOGDANOWICZ, J; SCHRÖDER, F. H et al.European urology. 1989, Vol 16, Num 4, pp 253-257, issn 0302-2838Article

Overdiagnosis and overtreatment of early detected prostate cancer : Treatment of localized prostate cancerBANGMA, C. H; ROEMELING, S; SCHRODER, F. H et al.World journal of urology (Print). 2007, Vol 25, Num 1, pp 3-9, issn 0724-4983, 7 p.Article

Transrectal ultrasonography in the followup of prostatic carcinoma patients: a new prognostic parameter? = Echographie transrectale dans la surveillance des malades ayant un cancer de la prostate: un nouveau paramètre pronostique?CARPENTIER, P. J; SCHRODER, F. H.The Journal of urology. 1984, Vol 131, Num 5, pp 903-905, issn 0022-5347Article

The story of the european randomized study of screening for prostate cancerSCHRÖDER, F. H; DENIS, L. J; ROOBOL, M et al.BJU international. Supplement (Print). 2003, Vol 92, Num 2, pp 1-13, issn 1465-5101, 13 p.Article

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)ROOBOL, M. J; KIRKELS, W. J; SCHRÖDER, F. H et al.BJU international. Supplement (Print). 2003, Vol 92, Num 2, pp 48-54, issn 1465-5101, 7 p.Article

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative groupROOBOL, Monique J; SCHRÖDER, F. H; ANKERST, Donna et al.World journal of urology (Print). 2012, Vol 30, Num 2, pp 149-155, issn 0724-4983, 7 p.Article

Anxiety and depression after prostate cancer diagnosis and treatment : 5-year follow-upKORFAGE, I. J; ESSINK-BOT, M.-L; JANSSENS, A. C. J. W et al.British journal of cancer. 2006, Vol 94, Num 8, pp 1093-1098, issn 0007-0920, 6 p.Article

ERSPC: features and preliminary results from the Antwerp study centreCOEBERGH, J. W; NEETENS, I; NEELS, H et al.BJU international. Supplement (Print). 2003, Vol 92, Num 2, pp 17-21, issn 1465-5101, 5 p.Article

Determining the cause of death in randomized screening trial(s) for prostate cancerDE KONING, H. J; BLOM, J; MAKINEN, T et al.BJU international. Supplement (Print). 2003, Vol 92, Num 2, pp 71-78, issn 1465-5101, 8 p.Article

Early diagnosis and treatment of localized prostate cancerBANGMA, C. H; HULAND, H; SCHRÖDER, F. H et al.European urology. 2001, Vol 40, Num 3, pp 1-10, issn 0302-2838Article

Prostate-specific antigen : A surrogate endpoint for screening new agents against prostate cancer?SCHRÖDER, F. H; KRANSE, R; BARBET, N et al.The Prostate. 2000, Vol 42, Num 2, pp 107-115, issn 0270-4137Article